Connect
← Return to Can anyone share their experience with Pluvicto?
Discussion
Can anyone share their experience with Pluvicto?
Prostate Cancer | Last Active: 17 hours ago | Replies (81)Comment receiving replies
Pluvicto was started as my PSA abruptly increased from a low of 8 after doxetaxel treatment to 17 a few months later. By the time Pluvicto was started the PSA was 198.
After the first infusion, the PSA dropped to 100. After the second infusion, up again to 120. After the third infusion, the PSA was 364 - obviously a treatment failure. Options now are essentially nonexistent. I am unwilling to accept the debilitating side effects of a repeat doxetaxel ( or other chemo agent) for minimal short term benefit.
Replies to "Pluvicto was started as my PSA abruptly increased from a low of 8 after doxetaxel treatment..."
A prostate-specific antigen (PSA) flare occurs in about 15% of metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel. This flare has no standard definition. Its impact on treatment efficacy is unclear. We sought to evaluate the incidence and characteristics of PSA flare on cabazitaxel, and its impact on survival.
https://www.sciencedirect.com/science/article/abs/pii/S0959804914002706#:~:text=A%20prostate%2Dspecific%20antigen%20(PSA,on%20treatment%20efficacy%20is%20unclear.
BTW my PSA flared from 41 to 159.3 Oncologists said must do 12 weeks then see just did second chemo I am 80 and feel great Mets in T5 and L4 and hip Pain first 4 days but on pain killer's Tylenol and some more powerful Options arc 177 or clinical trial OS maybe 13 to 25 months
WHAT about chemo with Cob?> Or this What is the most powerful chemo drug?
Red Devil Chemo: What to Know About Doxorubicin
Doxorubicin is one of the most powerful chemotherapy options for a wide range of cancers. Because of the way it works, doxorubicin can kill cancer cells at any point in their life cycle.Sep 28, 2023
Thank you for sharing! Mine is similar, and yet I am still fighting as you are! Stay strong!
Connect
Study PSA flare with both Chemo and 177
COPY Overall, 125 patients were included. Median PFS and OS were 6.5 and 13.3 months, respectively. Depending upon the definition used, flare incidence ranged from 8.3% to 30.6%. The flare lasted < 2.6 months. A PSA flare followed by a ⩾50% decrease was associated with a median PFS and OS of 11.2 and 25.2 months, respectively. Median PFS and OS for a ⩾30% rather than ⩾50% decrease were 10.4 and 16.5 months. These outcomes were not significantly different from those in patients with immediate PSA decreases of ⩾50% or ⩾30% from baseline, but were significantly better than in patients experiencing no PSA decrease (p = 0.006 and 0.015, respectively, for OS).
Conclusion
The PSA response to cabazitaxel, with or without initial flare, was associated with a strong survival benefit. The taxane-induced flare during the first 12 weeks of therapy can be ignored when evaluating PSA response.